- NewsCategory：
- All Company news Industry news
common83One result
-
1031
Gotham Therapeutics Establishes Advanced Oncolog✔✔€y Profiling Cascade with ProQinase to Progress itΩ✔s Portfolio of Epitranβ®∏φscriptomic Drug Candidates
Gotham Therapeutics Establishes Advan &×εced Oncology Profiling Cascade with εφ↑ProQinase to Progress its ♦>α≥Portfolio of Epitran•↓scriptomic Drug Candidatπ✔₩ esWEDNESDAY, OCTOBER 30, 2019Gotham Therapeuti£cs, a biotechnology company develo↕☆¥ping a novel drug class &•✔€targeting RNA-modifyin¥"™g proteins, and ProQinase, an early stage drug •-discovery company, re↔♠₩cently acquired by M™"∑alvern/PA-based Reaction Biology Corp.,≠÷§ today announced that they have established a"αn array of advanced biochemical and <Ωcellular assays to characteri××ze epitranscriptomic-directed compounds.“Est$φablishing tailored target engagement, cell biol☆ogy, phenotypic, and in-vivo assays to e≤$γδvaluate compounds originating from our three mos ✔→t advanced epitransc ©riptomic programs in parallel is a crucial n↓≤'ext step to develop our broad pipeline t→€∑owards the clinic,” said Dr. Gerhard Müller, Chiλ ef Scientific Officer of Gotham Therapeutics£ . “By pursuing the full ∞₩range of the reader-writer-eraser continuum,' '× we are able to focus on targets →¶with the most compelling links to ← disease and advance those ®•programs in tandem.”“Combining our high pr±¶¥₩oficiency in providing customiσ♥zed solutions as earl♠σ→y stage drug-discovery services, including tailor$•✔-made biochemical and ceα↑δ€ll-based assays, with Gotham♦♦✔ ’s expertise in epitranscriptom>÷★ics, we were able to establish in a very short® ← time a set of customized enzymatic a ∞±nd cellular assays for compounds addressing threeλ♥ different mRNA-modifying targets,” said Dr. Se←'bastian Dempe, Chief Executive Officer of∏'" ProQinase. “We look forward to su♦¶←★pporting Gotham as the compa§©∞↓ny advances its progra≥±®ms into lead optimization and to conΩλλ tinued work with the Gotham team assisting the'" company to advance its broad pipeline in a time-₹$←"effective manner.”In addition to establis₽ε$hing a tailor-made profilingφ™ cascade for compounds from it↑"↑→s three most advanced progra ms, Gotham has also made progress in strλengthening its drug discovery π₩α engine and developing its &♠candidate base. Gotham previously completeα≠d the gene-to-lead phase f ♣↔or its drug discovery project targeting the METTL₽×♦3/METTL14 complex and establi®shed a robust discovery proce<γ≈™ss as a platform for future proje>φ±cts. The company has also generaΩted a library of high-quality compounds ≈★tailor-made for accelerated hit generation λ&γ£and hit-to-lead expansion against large part☆₹ ≠s of the epitranscriptomic t♥γ¶arget space. This library includes a collection↑∑ of over 2,000 analo÷£≥gues covering over 80 distinct chemotypes that w∑δill be used to further accelerate Gotham $±≈’s drug discovery efforts as it expands its p₹↕ipeline.The original link:https©π£://www.pharmafocusasia.c<∞↕εom/news/gotham-therapeutics-¥δ'€establishes-advanced-oncology-profiling®Ω-cascade-with-proqinase-to-progres→∞↓s-its-portfolio-of-ep≥ itranscriptomic-drug-candidat↑♠•es2019 Asia-pacific pharma IP Lead↔♦₹er Summit: http://en.zenseegroupα✔♦₹.com/p/510934/will be held in Beijing ∞¥• on Novemberφ★ 14-15, and will attract α©more than 500 industry experts from $₹§domestic and foreign pharmaceutical com¶×↔panies, biotechnology companies, govern↕★ε≠ments, associations, law firms, intellα ectual property agents and other companie"®s to attend.Official registration a®€nd consultation channelsΩ:Contact：AnnPhone: 021-65650305Em≠Ωγail：Marketing@zensee★≈∞group.comhttp://en.zenseegro☆™↕up.com/p/510934 -
1030
Gilead and Glympse Bio Announce Strategic Colla$ ↑boration for Use of Biomarke✔♠ r Technology in NASH Clinical σ÷₹Development
Gilead and Glympse Bio Announce Strategic C↕÷₽ollaboration for Use of Biom∑ λarker Technology in NASH ↑€Clinical DevelopmentTUESDAY, O₩♦CTOBER 29, 2019Gilead Sc iences Inc. and Glympse Bio, Inc.φ¥, today announced that the companies h•δave entered into a strategic collaborationδ↕" in nonalcoholic steatohepatitis (NASH±×) clinical developmenα₹≈↑t. Glympse Bio’s proprietary synthetic bi♣✘omarkers – bioengineerφ$ed to identify stage and p∑♦≈→rogression of disease$₩≠ as well as early de₽♣βtection of treatment response – will be used to d∞©≠≤etermine clinical trial participants’ stage ∞™>↔of disease at initial screenin→☆g and to determine respo★≈↑nses to study treatment in Gilead’s NASH cli₹₩£$nical program.“We are excited about the opportu☆$£nity to partner with Glympse Bio to help®• inform our NASH developmentγ program,” said Mani Subramanian, MD, PhD♠≈ Senior Vice Preside♠✔®nt, Liver Diseases, Gilead Sciences. "䩧“By utilizing this innovα®ative technology, we hope ÷↑σ↕to better characterize this complex disease and i♦×mprove our understanding of how our comλ↑ε∏pounds impact disease progression.”Glympse Bio¥±’s proprietary technology, Glymp<£se Inside™, combines synthetic♠' biomarkers with machine learning approaches to ©≤identify the stage and monitor progressπ∏ion of important, complex dis€♦δ$eases such as cancer, fibrosis, ↑®₽inflammation, and infections, in real time.“We arφσe very excited about partner ★©ing with Gilead, a leader in dr<®<ug development, to help drive ea₽§∑rlier and more favorable outcomes for patients,” ∑→<±said Caroline J Loew, President and CEO,→★β$ Glympse Bio. “Gilead’s commitment to developi∏↕•ng innovative medicines in ✔★≈<areas of high unmet medical ♥↓♦need aligns with our mission of transforming di♣Ωsease detection and α πmeasuring treatment response, all with the go≠al of helping improve the'≈' lives of patients.”information&nbs p;source:pharma focus Asiα'aThe original link:https:https:http€"÷s://www.pharmafocusa→♦≠sia.com/news/gilead-and-glymps♣'e-bio-announce-strategic-collaboration-for-use-of÷₩♠₹-biomarker-technology-in-nash-clinical÷ -development2019 Asia-pacific pha™♣δ↑rma IP Leader Summit:§☆&¶http://en.zenseegroup.com/p/510934/ will ₹♦"↔be held in Beijing&nα÷bsp; on Novem€πber 14-15, and will attract more than 500 $÷industry experts from dom®→estic and foreign pharmaceutical comp÷✔£±anies, biotechnology companies, gover<'φ'nments, associations, law firms, intellect♣$ual property agents and other companies to atten₹≤d.Official registration and consultation channels↔↑÷φ:Contact：AnnPhone: 021-65650σ÷π305Email：Marketing@zen™π©←seegroup.comhttp://en.zenseegroup.com/p/5109↓™∑©34 -
1029
HistoIndex Announces &≤'Global Partnerships To Expand AI-Based D→λ igital Pathology Platform
HistoIndex Announces Global Par™"'tnerships To Expand AI-Based Digitalγ Pathology PlatformMONDAY, OCTOBER 28,✔β 2019HistoIndex announceγ₩s the expansion of its AI-based ™εdigital pathology platform towards lσ♠arge-scale NASH preclinical programs for p ≈&harmaceutical and biotech companies to achiev₽≥"e quantifiable and reproducible dat®δ★a on therapeutic responses in NAS₽₹H animal models, and to aid CROs as well as ™♠ research agencies in validating new modδ∑els mimicking the NASH disease.Published prec←≤linical studies have demonstra® ted the use of Histoβ♦ ¥Index's fully quantifiable Second Harmonic Gene•₹ration (SHG) technology as a hi"πghly accurate stain-free method tha♥×♦t can monitor the efficacy o☆'∞f various therapeutic agents, by quantifying more♠ than 450 NASH-associated parameters λ¥in fibrosis, inflammation, ballo↔εδoning and steatosis. The information of these♦δ NASH-associated parameters g±≈<βathered from the enti✔™πre liver tissue, provides com✔±prehensive insights on the mechan™↓ism of action of the ther♣∏♥apeutic agent. As a drug discovery t•✘ ool, HistoIndex's SHG-enabled digital pa&✘thology platform will all∞™÷ ow pharmaceutical and biotech compan>∞↔≥ies to select promising lead candidates for furt≠ her optimization and make infβ↑σormed decisions in the ma¶×γnagement of their NASH drug developmen¶¥•t pipeline.In addition to ongoing NASH clinical t×★®✔rials, HistoIndex is currentl☆®≥y involved in multiple preclinic×π©αal studies, most of which are conducted•₽₹' by major pharmaceut₩↕γical and biotech companies, medical uβαniversities, CROs and researchβ≤₩£ agencies. Notably, HistoIndex ελhas recently entered into a collabo↑♥ ration with the A*STAR's Genome Institute of Sing≥φ≤≠apore (GIS) to valid±£★ate their in vivo and in vitro NASH models↑<¥ based on Asian-centricφ> clinical data. Says Professor Patrick Ta↕€n, Executive Director of the₩→Ω∞ Genome Institute of Singapore ¶↕π(GIS), "At GIS, we co nduct our preclinical studies ¶on fatty liver involving data from✘£δ animal models based on patient-d♠λ☆erived transcriptomic data. This has a high trans↓φlational potential as it helps us t→→o pinpoint new therapeutic targets and their valπ≥€idation. Therefore, using a f ♠₹ully quantitative, reliable and object®₽™•ive pathological evaluation such as Histo≠↓•Index's AI-based digital patholog∏≠¶y platform is essential to the s ↔uccess of our efforts in therapeutic target discγ¶γovery."HistoIndex is also a pa$∏₽≤rtner with globally-reno∞¶ wned CRO, WuXi Apptec, in advancing their NASH≥↔π✔ preclinical programs wλ®•♠ith advanced R&D and smart imaging analys∞©is capabilities. Publi×<shed study data will be available for discussion↕ε ₩s during networking opportunities throughou™<t AASLD's The Liver ±Meeting® in November 2019. &←≥✔nbsp;"We are very excε₹→ited to extend our AI-ba÷±sed SHG platform to preclinical studies to he"•©lp companies with drug d☆¶iscovery programs select promising lead ca₩'"ndidates for further optimization and subsequ®®≈∑ent clinical development," says Dr Poon Thong≠∞ Yuen, Chief Executive Officer o∞ ∑f HistoIndex. "Our SHG•☆£ image analysis platform h♣φ♥as already been used to analyze the efficacy of a₹φ' series of promising drug candidat₽☆↑≤es for NASH within va✘∑Ωrious animal models commonly-used by the industrεβ←y, and we believe thes©§e preclinical partnerships will heφ§πlp drive the adoption o∏≤f our platform significantly."informati÷♠₩on source:pharma f♠∞ocus AsiaThe original link:https:htt<λ£ps://www.pharmafocusasia.com/news/histoind"↕ex-announces-global-partnerships-to-expand-ai-bαπ♦ased-digital-pathology-platfεσ orm2019 Asia-pacific pharma IP Leader Summit: h$"ttp://en.zenseegroup.com/p>σ/510934/will be held in σ±∞Beijing on November 1×☆÷4-15, and will attract more than Ω≤ 500 industry experts from domestic and £♠↓foreign pharmaceutical companies, biotechnology ≥≠companies, governments,↑¥ associations, law firms, intellectual pr¶×₩ operty agents and other companies to attend.Offi©∑cial registration and consultation channe•∞ls:Contact：AnnPhone: 021-65650£≠305Email：Marketing@zeλ↓nseegroup.comhttp://en.zenseegroup.c£₹✘ om/p/510934 -
1028
AVROBIO Receives Orphan-Drβ $ug Designation from the U.S. FDA for AVR‑RD‑02 f♣★∏or the Treatment of Gaucher Disease
AVROBIO Receives Orphan-Drug Designati≠₹λ±on from the U.S. FDA fo∞∞r AVR‑RD‑02 for the Tr'eatment of Gaucher DδγiseaseFRIDAY, OCTOBER 25, 2•✘φ019AVROBIO, Inc., today ₽≤'¶announced that the U.S. Food and D∏ rug Administration (FDA) has granted≈₩≈ orphan-drug designation for the Company₩γ↓&’s investigational g♠←¶&ene therapy, AVR-RD-02, for the treatment of ™↑←∞Gaucher disease. AVR-RD-02 consists of α® the patient’s own hematopoietic&← stem cells, genetical®Ω¥ly modified to express glucocerebrosidase (∞∞λGCase), the enzyme that §λis deficient in Gaucher disease. Th÷&≠e Company is actively recr©☆$♠uiting in Canada for its Phase 1/2 clinica≥∑γ&l trial of AVR-RD-02, which seeks to eva₩☆¥luate the safety and efficacy of the therapy 𠀶in patients with Type 1 Gaucher disea×₹≠Ωse.“Under the existing stδ₹∏andard of care, patients with Gaucher disea♦→λ☆se are bound to a lifelong infusion s♥♦πλchedule of enzyme replacement therδΩ•apies, and still experience painful and pr ✘βogressive symptoms such as debilita✔∑ting musculoskeletal pain an¥>d fatigue,” said Birgitte Volck, MD, PhD, Preside©Ω↓nt of Research and Development at AVROBIO. “Orp>σ han-drug designation recognizeε>s the unmet need of populations with rare diseasγ♦&πes like Gaucher where$✘ AVROBIO strives to ≤☆£transform lives by addressing→♠σ• the underlying cause of the di©☆±↕sease with a single dose of gene therapy.”Orph♥∞∞γan-drug designation iβ≥<¥s granted by the FDA to dru±ε♣↓gs and biologics which are inten™÷ded for the safe and effective treatment, diagnβ ♣osis or prevention of rare diseases or condit¶↑'ions that affect fewer than 200,000 p§ eople in the United States. Or÷ε≠phan-drug designatioεΩn provides certain incentives, which may γ→β×include tax credits towards the co∑±st of clinical trialsσ€ε and prescription drug us∞★♣er fee waivers.information source:pharσ ma focus AsiaThe original link:ht ↔γtps:https://www.pharma¶∞×≤focusasia.com/news/avr♠×obio-receives-orphan-drug¥≥β-designation-from-the-us-≤™♦fda-for-avrrd02-for-the-treatment-of-gauΩ✘cher-disease2019 Asia-pacific phar"≥ ma IP Leader Summit: htσ≠tp://en.zenseegroup.com/p/510934/w✘&₹ill be held in Beijing on&nb"₽®αsp;November 14-15, and will att∏©>ract more than 500 industry experts fro'↔m domestic and foreign pharmaceutγ↓ical companies, biotechnology companies, governm<←γ¥ents, associations, law firms, intellectual propΩ"®erty agents and other companies to attend.Official registration and c♥¶onsultation channels:Contact：AnnPho♦♣ne: 021-65650305Email：Marketing@ze&•§nseegroup.comhttp://eΩ∏n.zenseegroup.com/p/510934 -
1026
AZTherapies Strengthens Neuroinflammati↔δεon-Targeted Pipeline Through Acquisitio≤♦δn of Smith Therapeutics
FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., a bio₹ §εpharmaceutical company d★♠eveloping therapeutics € to extend brain health, today announced tπ&he acquisition of Smith Therapeutics, a pβ₩↑rivate biopharmaceutical company with a sha ₹✔red goal of targeting neuroinflamm♥γ→ation to treat neurodeεΩ★generative disease. Sm ≤♣ith Therapeutics’ Founder and Chief E×±&xecutive Officer Phil≤β>≤ip Ashton-Rickardt, Ph.D.,δ₩≥ has joined the senior leadership te±≠®am at AZTherapies as Senior Vic¥φe President of Immunology. Financial terms of th¶e acquisition were not di±>sclosed.Smith Therapeutics’ proprλ£ietary research platform focuses on the use o♣ α®f modified T cells to restore a healthy balan&×ce of inflammatory and regulatoα♠©ry cells in the brain. To date, Sm♥φ¶ith has successfully engineered immunosuφ₽ppressive T regulatory (Treg) cells €<♠βwith Chimeric Antigen Receptors (CARs) targetingδ₹± brain glial cells. Previous research has ✔↔≈demonstrated the ability of Tregσ≠s to dampen microglial activity and reduc∑ ®e neuroinflammation in models of neurodegenerati÷€→on, suggesting their potential utility iΩ≥↔n the treatment of diseases including Progressiσ'≠ve Supranuclear Palsy (PSP), Alzheimer’s disease,$≤£♣ Parkinson’s disease, Huntington’s dis€δease, Amyotrophic Lateral Scle¥↕♣rosis (ALS), and others.“T★♦his acquisition represen"™↕ts a meaningful step forward for us as we c♦ εγontinue to strengthen our leadership ≥♦position in the development of therapies t βδ&argeting neuroinflammation to stop or slow the p♦Ωrogression of neurodegenerativ≤φe diseases,” said David R. Elmaleh, Ph.D.↕★©™, Founder, CEO, and Chairman of AZTherapies. “We ↔↑γ≠are excited to be working with Philip as we add ≥←•this cutting-edge techn¥♣™♦ology to our portfolio of inno♥ vative programs. An esteemed i€mmunologist and inventor of the tec§÷'hnology, Philip bring¶₩&πs unparalleled expertise♦" to the company and we look forward₹↕ to advancing this CAR-Treg prog✘←ram further into IND-enabling studies anγ®d into clinical development as rapidly as possi✔₩$ble.”Dr. Ashton-Rickardt cπ♣ommented on the acquisition and h≈♠÷is appointment: “Our shared ra♥₹tionale of targeting neuroinfl☆αβ↕ammation as the root cause of neurode® generative disease makes th₹β☆"is acquisition a great strategic f♠εit for us. With AZTherapies’ expertise in d ∞rug development and clini•♣σcal trial execution, we believe that toget$♣φher, we are well position★•ed to advance our CAR-Treg technology and fu©★ndamentally change neurodegenerative"Ω disease progression.”Prior to launch♥♣ ing Smith Therapeuticsδ↔¶ in 2017, Dr. Ashton-Rickardt was Ch₽λ¶₹air in Immunology at Imperial Colle'δge London, Visiting Pr÷δ♣ofessor, Brigham and W β÷®omen’s Hospital, Harvard Medical School, and Ass₽♥Ωociate Professor in the Department ₩©of Pathology at the University of C¥hicago. His work has been recog♠≤&nized by his peers through the award of tenur®≈&αe from The University of Chicago an ♦✔d by his fellow citizens as a recip↕×★σient of the Early Career Award ≥<for Scientists and Engineers from President B¥♦₹ ill Clinton. He has pub∑↓δlished more than 65 peer-reviewed papers →®Ω©in more than 30 academic journal¥>s (including Cell, Scien≤∏ce, Immunity, and Nature Immunology)★₹∑, has served as an ed♦♦♦•itor for several academic journals, and ha↑≠₩s been a member of g¥®ε rant review boards glo"γ♥bally. Dr. Ashton-Rickardt received a B.Sc. in ♥αBiochemistry from the University of L₩σΩ ondon, King’s College ←&δβwith honors, a Ph.D. in Molecular Biol®∑ελogy from the University of Edinburgh, and comple÷★ted post-doctoral work at the Un∞€iversity of Edinburgh and the Massachusetts Iφπnstitute of Technolo∏★gy in Molecular Biology→ ♠α and Molecular Immunology, respectively.in<≥formation source:pharma focu♠¶ s AsiaThe original link♠ :https:https://www.pharmafocusasia.com/n∑≥∏ews/aztherapies-strengthens-neuroinflam§≥¶♠mation-targeted-pipeline-through-acquisi¥ tion-of-smith-therapeutics2019 As•ε®δia-pacific pharma IP Leaπεder Summit: http://en.zenseegroup.com/p/5109₩↔34/will be held in Beijing on∏©"★ November 14-15, and will att>≥ract more than 500 indust ♣©ry experts from domestic and foreign pharmace'γutical companies, biotechnology companies♠×, governments, associations, law firms, inte≤§εllectual property agents and other compani≥¥÷↔es to attend.Official registratio←±n and consultation channels:Contact：AnnPh↔™ ☆one: 021-65650305Email：Mar€β☆↕keting@zenseegroup.co♠←λmhttp://en.zenseegroup.c∏₩om/p/510934
Contact Us
Zensee_Daystar online
© 2011-2016